Month: November 2022

Ali, Ahmed R.; El-Bendary, Eman R.; Ghaly, Mariam A.; Shehata, Ihsan A. published an article in 2018, the title of the article was Synthesis, in vitro anticancer evaluation, and in silico studies of new thiazolo[3,2-a]pyrimidin-5-one derivatives.COA of Formula: C6H8O3 And the article contains the following content:

Synthesis of thiazolo[3,2-a]pyrimidin-5-ones derivatives I [R = H, Me, Cl] and II [R1 = Me, NH2; X = NH, O] were developed and evaluated against antitumor activity. The target compounds I and II showed observed activity against Renal UO-31 cancer cell line with cell growth promotion 52.72%-64.52%. Assessment of toxicities, drug likeness and drug score profiles were reported. Some of the synthesized compounds showed good docking scores with potential anticancer targets. In vitro anticancer evaluation, together with in silico studies, revealed that compounds I [R = Me, Cl] and II [R = R1 = Me; X = O] were the most active members in this study. The experimental process involved the reaction of 3-Acetyldihydrofuran-2(3H)-one(cas: 517-23-7).COA of Formula: C6H8O3

The Article related to thiazolopyrimidinone preparation antitumor human docking, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C6H8O3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 26, 2012, Badiger, Sangamesh; Behnke, Dirk; Betschart, Claudia; Cotesta, Simona; Hintermann, Samuel; Ofner, Silvio; Pandit, Chetan; Roy, Bernard Lucien published a patent.Synthetic Route of 1198284-94-4 The title of the patent was Preparation of diazaspiro[5.5]undecanes as orexin receptor inhibitors. And the patent contained the following:

The title compounds I [A = (un)substituted 5-6 membered aromatic ring which contain 1-4 heteroatoms selected from N, O and S; m, n = 0-6; R1, R2 = halo alkyl, cycloalkyl, etc.; X1 = C(O) and X2 = N(LB); or X1 = N(LB) and X2 = C(O); L = C(R6)2; R6 = H, alkyl, cycloalkyl, etc.; or two R6 together with the carbon atom to which they are bound form cycloalkyl; B = (un)substituted 5-6 membered monocyclic or 8-10 membered fused bicyclic aromatic ring which may contain 1-4 heteroatoms selected from N, O and S], useful as orexin receptor inhibitors, were prepared E.g., a multi-step synthesis of II, starting from 2,9-diazaspiro[5.5]undecan-1-one trifluoroacetate and 2-chloro-4,6-dimethylpyrimidine, was described. Exemplified compounds I were tested for inhibiting human orexin 1 and human orexin 2 receptors (data given). Pharmaceutical composition comprising the compound I was disclosed. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Synthetic Route of 1198284-94-4

The Article related to diazaspiroundecane preparation orexin receptor inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 1198284-94-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 4, 2017, Makrerougras, Mehdi; Coffinier, Romain; Oger, Samuel; Chevalier, Arnaud; Sabot, Cyrille; Franck, Xavier published an article.SDS of cas: 3976-69-0 The title of the article was Total Synthesis and Structural Revision of Chaetoviridins A. And the article contained the following:

The first synthesis of the proposed structures of chaetoviridins A has been achieved in 10 steps by controlling the syn- or anti-aldol side chain. The angular lactone has been regioselectively introduced by condensation of a chiral dioxin-4-one to cazisochromene. Comparison of the NMR and CD data of the synthesized and reported natural products led to the complete reassignment of chaetoviridin A to I and renaming of the chaetoviridins. The experimental process involved the reaction of (R)-Methyl 3-hydroxybutanoate(cas: 3976-69-0).SDS of cas: 3976-69-0

The Article related to chaetoviridin a synthesis absolute configuration revision, Biomolecules and Their Synthetic Analogs: Other Bacterial and Fungal Metabolites and other aspects.SDS of cas: 3976-69-0

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Dowgiallo, Matthew G.; Miller, Brandon C.; Kassu, Mintesinot; Smith, Kenneth P.; Fetigan, Andrew D.; Guo, Jason J.; Kirby, James E.; Manetsch, Roman published an article in 2022, the title of the article was The convergent total synthesis and antibacterial profile of the natural product streptothricin F.Reference of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate And the article contains the following content:

A convergent, diversity-enabling total synthesis of the natural product streptothricin F has been achieved. Herein, authors describe the potent antimicrobial activity of streptothricin F and highlight the importance of a total synthesis that allows for the installation of practical divergent steps for medicinal chem. exploits. Key features of synthesis include a Burgess reagent-mediated 1,2-anti-diamine installation, diastereoselective azidation of a lactam enolate, and a mercury(II) chloride-mediated desulfurization-guanidination. The development of this chem. enables the synthesis and structure-activity studies of streptothricin F analogs. The experimental process involved the reaction of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate(cas: 2873-29-2).Reference of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate

The Article related to streptothricin f convergent total synthesis antibacterial, Biomolecules and Their Synthetic Analogs: Other Bacterial and Fungal Metabolites and other aspects.Reference of (2R,3S,4R)-2-(Acetoxymethyl)-3,4-dihydro-2H-pyran-3,4-diyl diacetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 20, 2020, Cao, Ping; Zhang, Chao; Bishop, Michael J. published a patent.Computed Properties of 201811-20-3 The title of the patent was Preparation of novel pyridinylpyrimidines as FGFR inhibitors for the treatment of cancer. And the patent contained the following:

The invention provides the title compounds I [each R1-R5 = (independently) H, F, Cl, Br, alkyl, etc.; R6 = (CH2)0-5CH:CH2, (CH2)0-5CCH, NHCO(CH2)0-5CH:CH2, etc.; Linker = (un)substituted alkyl, COalkyl, CO2alkyl, etc.] or optically pure stereoisomers, solvates, or pharmaceutically acceptable salts thereof with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. E.g., a multi-step synthesis of II, starting from 4-amino-3-nitro-phenol and tert-Bu 3-iodoazetidine-1-carboxylate, was described. Exemplified compounds I were evaluated for FGFR inhibition (data given). These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer. The experimental process involved the reaction of tert-Butyl (4-hydroxy-2-nitrophenyl)carbamate(cas: 201811-20-3).Computed Properties of 201811-20-3

The Article related to pyridinylpyrimidine preparation fgfr4 inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 201811-20-3

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On September 16, 2004, Gonzales, Jesus E., III; Wilson, Dean Mitchell; Termin, Andreas Peter; Grootenhuis, Peter Diederik Jan; Zhang, Yulian; Petzoldt, Benjamin John; Fanning, Lev Tyler Dewey; Neubert, Timothy Donald; Tung, Roger D.; Martinborough, Esther; Zimmermann, Nicole published a patent.Related Products of 141940-37-6 The title of the patent was Preparation of quinazolines as modulators of ion channels. And the patent contained the following:

The title compounds [I; NR1R2 = (un)substituted 3-12 membered monocyclic or bicyclic (un)saturated ring having 0-3 heteroatoms selected from N, S or O; ring A = (un)substituted 5-7 membered aryl or 8-10 membered bicyclic aryl having 0-3 heteroatoms selected from N, S or O; x = 0-4; R3 = QR (wherein Q = a bond, alkylidene wherein up to two non-adjacent methylene units are optionally replaced by S, O, CS, etc.; R = halo, NO2, CN, etc.)], useful as inhibitors of voltage-gated sodium channels and calcium channels, were prepared Thus, reacting 2-(4-chloro-7-methylquinazolin-2-yl)phenol with 4-aminopiperidine in the presence of Et3N in CH2Cl2 afforded 89% II. Representative compounds I were found to possess desired N-type calcium channel modulation activity and selectivity (no specific data given). Also, representative compounds I were found to possess desired voltage gated sodium channel activity and selectivity (no specific data given). The invention also provides pharmaceutically acceptable compositions comprising the compounds I and methods of using the compositions in the treatment of various disorders. The experimental process involved the reaction of tert-Butyl (4-(trifluoromethyl)phenyl)carbamate(cas: 141940-37-6).Related Products of 141940-37-6

The Article related to quinazoline preparation modulator sodium calcium ion channel, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Related Products of 141940-37-6

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 25, 2011, Brain, Christopher Thomas; Cho, Young Shin; Giraldes, John William; Lagu, Bharat; Levell, Julian; Luzzio, Michael; Perez, Lawrence Blas; Wang, Yaping; Yang, Fan published a patent.Recommanded Product: 1198284-94-4 The title of the patent was Preparation of pyrrolopyrimidine derivatives for use as CDK4/6 inhibitors. And the patent contained the following:

Title compounds I [A = CH or N; L = bond, C(O), or S(O)2; R1 = alkyl, (un)substituted cycloalkyl, PH, piperidinyl, or tetrahydropyranyl; R2 = (un)substituted diazabycycloheptanyl, diazaspirononanyl, diazabicyclooctanyl, etc.; R4 = H, D, CH3, etc.; R8, R9, R10, and R11 independently = H or D], and their pharmaceutically acceptable salts, are prepared and disclosed as cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors. Thus, e.g., II was prepared by a multistep procedure (preparation given). Select I were evaluated in CDK4/cyclin D1 enzymic activity assays, e.g., II demonstrated an IC50 value of 0.008 to 0.016 μM. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Recommanded Product: 1198284-94-4

The Article related to pyrimidine pyrrolo derivative preparation cdk4 cdk6 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 1198284-94-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 8, 2020, Fu, Zhifei; Luo, Miaorong; Zhang, Yang; Cai, Yalei; Zhu, Wu; Li, Jian; Chen, Shuhui published a patent.Safety of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate The title of the patent was Nitrogen-containing spiro derivative as RET inhibitor. And the patent contained the following:

The invention disclosed a kind of nitrogen-containing spiro derivative as RET inhibitor. The claimed compound is shown in structure I (T = CN or N; R1,R2,R3 = H, halo, C1-6 alkyl, etc.; R4 = H, amino, hydroxy, etc.; D1,D2 = (un)substituted -CH2CH2-; D3 = methylene, carbonyl, etc.; D4 = ethylene, propylene, -OCH2CH2-, etc.). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can be used as RET inhibitor for treating RET mediated disease. The experimental process involved the reaction of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate(cas: 1198284-94-4).Safety of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

The Article related to nitrogen containing spiro derivative preparation ret inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of tert-Butyl 1-oxo-2,9-diazaspiro[5.5]undecane-9-carboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Gupta, Poonam published an article in 2021, the title of the article was Synthesis of related substances of antipsychotic drug Risperidone.SDS of cas: 517-23-7 And the article contains the following content:

European pharmacopeia related substances I [ R1 = H, CH3; R2 = (5-fluoro-1,2-benzoxazol-3-yl), (4-fluoro-2-hydroxy-benzoyl) etc] (impurities) was obtained during the synthesis of Risperidone. Described the detection, origin, synthesis, characterization and control of the related substances, which was improved the com. process. The experimental process involved the reaction of 3-Acetyldihydrofuran-2(3H)-one(cas: 517-23-7).SDS of cas: 517-23-7

The Article related to methyl piperidyl ethyl tetrahydropyridopyrimidinone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 517-23-7

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 28, 2018, Grew, Andrew P.; Zimmermann, Kurt; Wang, Jing; Berlin, Michael; Dong, Hanqing; Ishchenko, Alexey; Qian, Yimin; Crews, Craig M.; Jaime-Figueroa, Saul; Burslem, George published a patent.Name: tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate The title of the patent was Preparation of heterocyclic compounds as EGFR proteolysis targeting chimeric molecules and associated methods of use. And the patent contained the following:

The disclosure relates to bifunctional compounds of formula I, which find utility as modulators of receptor tyrosine kinase (RTK) proteins. The disclosure is directed to bifunctional compounds of formula I, which contain on one end a ligand which binds to an E3 ubiquitin ligase and on the other end a moiety which binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effectuate ubiquitination, and therefore, degradation (and inhibition) of the target protein. The disclosure exhibits a broad range of pharmacol. activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the disclosure. Compounds of formula I wherein ULM is a small mol. E3 ubiquitin ligase binding moiety; PTM is a small mol. receptor tyrosine kinase protein targeting moiety; L is a bond and a chem. linking moiety; and pharmaceutically acceptable salts, enantiomers, stereoisomers, solvates, polymorphs and prodrugs thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluate for their EGFR inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values of in the range of 0.0021 μM to 12 μM. The experimental process involved the reaction of tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate(cas: 882518-89-0).Name: tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

The Article related to heterocycle preparation egfr proteolysis targeting chimeric mol, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: tert-Butyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics